Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5389947 | 1.00 | TRPA1 (0.52) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL5390593 | 0.85 | SMN1; SMN2 (0.49) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL5388430 | 0.85 | SMN1; SMN2 (0.49) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL5388435 | 0.85 | SMN1; SMN2 (0.49) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL14446991 | 0.83 | L3MBTL1 (0.47) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL5390614 | 0.82 | TDP1 (0.51) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL5390620 | 0.82 | TDP1 (0.51) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL11963251 | 0.77 | CYP11B1 (0.61) | TRPA1GAASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL5380952 | 0.76 | APP (0.37) | GAASMN1; SMN2APP | |
| SCHEMBL29347118 | 0.76 | TRPA1 (0.46) | TRPA1CYP11B1CYP11B2GPR119EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1373258-B1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-6828333-B2 | Treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1373258-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| WO-2002060896-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | TRPA1 4178/4885GAA 181/4885SMN1; SMN2 3836/4885 |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PDE4A, PDE4B, PDE3B | TRPA1 3117/4885GAA 2336/4885SMN1; SMN2 2619/4885 |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE4B | TRPA1 4281/4885GAA 1502/4885SMN1; SMN2 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.